Volkers A, Straatmijer T, Duijvestein M, Sales A, et al. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther 2022;56:1044-1054.
PMID: 35869807